Dendritic Cell Vaccine for Patients With Brain Tumors

Inclusion Criteria

• •PATIENT ELIGIBILITY
• •1. Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV {anaplastic astrocytoma (AA), anaplastic astro-oligodendroglioma (AO), or glioblastoma (GBM)} will be eligible for this protocol.
• •2. Patients must have had surgical resection at UCLA (University of California, Los Angeles), for which a separate informed consent was signed for the collection of their tumor prior to surgery.
• •3. After surgery, a pathological diagnosis of malignant glioma (WHO Grade III or IV) will need to be established.
• •4. Patients must be 18 years or older and able to read and understand the informed consent document. Patients must sign the informed consent indicating that they are aware of the investigational nature of this study.
• •5. Patients must have a Karnofsky performance status (KPS) rating of \> 60 prior to initiating treatment. Patients may be enrolled at a KPS of \< 60 if it is felt that the patient will have adequate opportunity to recover to a KPS of \> 60 by the initiation of treatment.